Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 13 to 24 of 36 entries
Sorted by: Best Match Show Resources per page
Granulocyte function in elderly patients receiving chemotherapy for aggressive non-Hodgkin's lymphoma. Effect of granulocyte colony-stimulating factor.

European journal of internal medicine

Osby E, Björkholm M, Lundahl J, Forslid J.
PMID: 12384135
Eur J Intern Med. 2002 Oct;13(7):448. doi: 10.1016/s0953-6205(02)00137-1.

BACKGROUND: Treatment with granulocyte colony-stimulating factor (G-CSF) is given in order to mitigate chemotherapy-induced granulocytopenia and the risk of infectious complications, which constitute a major threat to elderly patients, in particular, with malignant disorders. The aim of this study...

Cite
Osby E, Björkholm M, Lundahl J, et al. Granulocyte function in elderly patients receiving chemotherapy for aggressive non-Hodgkin's lymphoma. Effect of granulocyte colony-stimulating factor. Eur J Intern Med. 2002;13(7):448doi: 10.1016/s0953-6205(02)00137-1.
Osby, E., Björkholm, M., Lundahl, J., & Forslid, J. (2002). Granulocyte function in elderly patients receiving chemotherapy for aggressive non-Hodgkin's lymphoma. Effect of granulocyte colony-stimulating factor. European journal of internal medicine, 13(7), 448. https://doi.org/10.1016/s0953-6205(02)00137-1
Osby, Eva, et al. "Granulocyte function in elderly patients receiving chemotherapy for aggressive non-Hodgkin's lymphoma. Effect of granulocyte colony-stimulating factor." European journal of internal medicine vol. 13,7 (2002): 448. doi: https://doi.org/10.1016/s0953-6205(02)00137-1
Osby E, Björkholm M, Lundahl J, Forslid J. Granulocyte function in elderly patients receiving chemotherapy for aggressive non-Hodgkin's lymphoma. Effect of granulocyte colony-stimulating factor. Eur J Intern Med. 2002 Oct;13(7):448. doi: 10.1016/s0953-6205(02)00137-1. PMID: 12384135.
Copy Download .nbib Format: NLM
Survival, causes of death, and the prognostic role of comorbidities in chronic lymphocytic leukemia in the pre-ibrutinib era: A population-based study.

European journal of haematology

Steingrímsson V, Lund SH, Dickman PW, Weibull CE, Björkholm M, Landgren O, Kristinsson SY.
PMID: 34714556
Eur J Haematol. 2022 Feb;108(2):145-153. doi: 10.1111/ejh.13720. Epub 2021 Nov 11.

OBJECTIVE: To evaluate temporal trends in survival and causes of death in patients with chronic lymphocytic leukemia (CLL) in a nationwide study.METHODS: The cohort consisted of 13,009 Swedish CLL patients diagnosed 1982-2013. Relative survival (RS) and excess mortality rate...

Cite
Steingrímsson V, Lund SH, Dickman PW, et al. Survival, causes of death, and the prognostic role of comorbidities in chronic lymphocytic leukemia in the pre-ibrutinib era: A population-based study. Eur J Haematol. 2021;108(2):145-153doi: 10.1111/ejh.13720.
Steingrímsson, V., Lund, S. H., Dickman, P. W., Weibull, C. E., Björkholm, M., Landgren, O., & Kristinsson, S. Y. (2022). Survival, causes of death, and the prognostic role of comorbidities in chronic lymphocytic leukemia in the pre-ibrutinib era: A population-based study. European journal of haematology, 108(2), 145-153. https://doi.org/10.1111/ejh.13720
Steingrímsson, Vilhjálmur, et al. "Survival, causes of death, and the prognostic role of comorbidities in chronic lymphocytic leukemia in the pre-ibrutinib era: A population-based study." European journal of haematology vol. 108,2 (2022): 145-153. doi: https://doi.org/10.1111/ejh.13720
Steingrímsson V, Lund SH, Dickman PW, Weibull CE, Björkholm M, Landgren O, Kristinsson SY. Survival, causes of death, and the prognostic role of comorbidities in chronic lymphocytic leukemia in the pre-ibrutinib era: A population-based study. Eur J Haematol. 2022 Feb;108(2):145-153. doi: 10.1111/ejh.13720. Epub 2021 Nov 11. PMID: 34714556.
Copy Download .nbib Format: NLM
Intrinsic 5-lipoxygenase activity regulates migration and adherence of mantle cell lymphoma cells.

Prostaglandins & other lipid mediators

Xia C, Sadeghi L, Strååt K, Merrien M, Wright AP, Sander B, Xu D, Österborg A, Björkholm M, Claesson HE.
PMID: 34116165
Prostaglandins Other Lipid Mediat. 2021 Oct;156:106575. doi: 10.1016/j.prostaglandins.2021.106575. Epub 2021 Jun 08.

Human B-lymphocytes express 5-lipoxygenase (5-LOX) and 5-LOX activating protein (FLAP) and can convert arachidonic acid to leukotriene B

Cite
Xia C, Sadeghi L, Strååt K, et al. Intrinsic 5-lipoxygenase activity regulates migration and adherence of mantle cell lymphoma cells. Prostaglandins Other Lipid Mediat. 2021;156:106575doi: 10.1016/j.prostaglandins.2021.106575.
Xia, C., Sadeghi, L., Strååt, K., Merrien, M., Wright, A. P., Sander, B., Xu, D., Österborg, A., Björkholm, M., & Claesson, H. E. (2021). Intrinsic 5-lipoxygenase activity regulates migration and adherence of mantle cell lymphoma cells. Prostaglandins & other lipid mediators, 156106575. https://doi.org/10.1016/j.prostaglandins.2021.106575
Xia, Chuanyou, et al. "Intrinsic 5-lipoxygenase activity regulates migration and adherence of mantle cell lymphoma cells." Prostaglandins & other lipid mediators vol. 156 (2021): 106575. doi: https://doi.org/10.1016/j.prostaglandins.2021.106575
Xia C, Sadeghi L, Strååt K, Merrien M, Wright AP, Sander B, Xu D, Österborg A, Björkholm M, Claesson HE. Intrinsic 5-lipoxygenase activity regulates migration and adherence of mantle cell lymphoma cells. Prostaglandins Other Lipid Mediat. 2021 Oct;156:106575. doi: 10.1016/j.prostaglandins.2021.106575. Epub 2021 Jun 08. PMID: 34116165.
Copy Download .nbib Format: NLM
Diabetes mellitus and risk of plasma cell and lymphoproliferative disorders in 94,579 cases and 368,348 matched controls.

Haematologica

Shah UA, Rögnvaldsson S, Derkach A, Björkholm M, Turesson I, David Y, Hultcrantz M, Tan C, Hassoun H, Korde N, Lesokhin A, Mailankody S, Kristinsson SY, Landgren CO.
PMID: 34474548
Haematologica. 2022 Jan 01;107(1):284-286. doi: 10.3324/haematol.2021.278772.

No abstract available.

Cite
Shah UA, Rögnvaldsson S, Derkach A, et al. Diabetes mellitus and risk of plasma cell and lymphoproliferative disorders in 94,579 cases and 368,348 matched controls. Haematologica. 2022;107(1):284-286doi: 10.3324/haematol.2021.278772.
Shah, U. A., Rögnvaldsson, S., Derkach, A., Björkholm, M., Turesson, I., David, Y., Hultcrantz, M., Tan, C., Hassoun, H., Korde, N., Lesokhin, A., Mailankody, S., Kristinsson, S. Y., & Landgren, C. O. (2022). Diabetes mellitus and risk of plasma cell and lymphoproliferative disorders in 94,579 cases and 368,348 matched controls. Haematologica, 107(1), 284-286. https://doi.org/10.3324/haematol.2021.278772
Shah, Urvi A, et al. "Diabetes mellitus and risk of plasma cell and lymphoproliferative disorders in 94,579 cases and 368,348 matched controls." Haematologica vol. 107,1 (2022): 284-286. doi: https://doi.org/10.3324/haematol.2021.278772
Shah UA, Rögnvaldsson S, Derkach A, Björkholm M, Turesson I, David Y, Hultcrantz M, Tan C, Hassoun H, Korde N, Lesokhin A, Mailankody S, Kristinsson SY, Landgren CO. Diabetes mellitus and risk of plasma cell and lymphoproliferative disorders in 94,579 cases and 368,348 matched controls. Haematologica. 2022 Jan 01;107(1):284-286. doi: 10.3324/haematol.2021.278772. PMID: 34474548; PMCID: PMC8719074.
Copy Download .nbib Format: NLM
Diabetes mellitus and risk of plasma cell and lymphoproliferative disorders in 94,579 cases and 368,348 matched controls.

Haematologica

Shah UA, Rögnvaldsson S, Derkach A, Björkholm M, Turesson I, David Y, Hultcrantz M, Tan C, Hassoun H, Korde N, Lesokhin A, Mailankody S, Kristinsson SY, Landgren CO.
PMID: 34474548
Haematologica. 2022 Jan 01;107(1):284-286. doi: 10.3324/haematol.2021.278772.

No abstract available.

Cite
Shah UA, Rögnvaldsson S, Derkach A, et al. Diabetes mellitus and risk of plasma cell and lymphoproliferative disorders in 94,579 cases and 368,348 matched controls. Haematologica. 2022;107(1):284-286doi: 10.3324/haematol.2021.278772.
Shah, U. A., Rögnvaldsson, S., Derkach, A., Björkholm, M., Turesson, I., David, Y., Hultcrantz, M., Tan, C., Hassoun, H., Korde, N., Lesokhin, A., Mailankody, S., Kristinsson, S. Y., & Landgren, C. O. (2022). Diabetes mellitus and risk of plasma cell and lymphoproliferative disorders in 94,579 cases and 368,348 matched controls. Haematologica, 107(1), 284-286. https://doi.org/10.3324/haematol.2021.278772
Shah, Urvi A, et al. "Diabetes mellitus and risk of plasma cell and lymphoproliferative disorders in 94,579 cases and 368,348 matched controls." Haematologica vol. 107,1 (2022): 284-286. doi: https://doi.org/10.3324/haematol.2021.278772
Shah UA, Rögnvaldsson S, Derkach A, Björkholm M, Turesson I, David Y, Hultcrantz M, Tan C, Hassoun H, Korde N, Lesokhin A, Mailankody S, Kristinsson SY, Landgren CO. Diabetes mellitus and risk of plasma cell and lymphoproliferative disorders in 94,579 cases and 368,348 matched controls. Haematologica. 2022 Jan 01;107(1):284-286. doi: 10.3324/haematol.2021.278772. PMID: 34474548.
Copy Download .nbib Format: NLM
Cumulative exposure to melphalan chemotherapy and subsequent risk of developing acute myeloid leukemia and myelodysplastic syndromes in patients with multiple myeloma.

European journal of haematology

Jonsdottir G, Björkholm M, Turesson I, Hultcrantz M, Diamond B, Porwit A, Landgren O, Kristinsson SY.
PMID: 33966293
Eur J Haematol. 2021 Aug;107(2):275-282. doi: 10.1111/ejh.13650. Epub 2021 May 28.

OBJECTIVES: The aim of this study was to determine risk factors for development of acute myeloid leukemia/myelodysplastic syndromes (AML/MDS) in patients with multiple myeloma (MM).METHODS: We identified all patients diagnosed with MM in Sweden from January 1st, 1958 to...

Cite
Jonsdottir G, Björkholm M, Turesson I, et al. Cumulative exposure to melphalan chemotherapy and subsequent risk of developing acute myeloid leukemia and myelodysplastic syndromes in patients with multiple myeloma. Eur J Haematol. 2021;107(2):275-282doi: 10.1111/ejh.13650.
Jonsdottir, G., Björkholm, M., Turesson, I., Hultcrantz, M., Diamond, B., Porwit, A., Landgren, O., & Kristinsson, S. Y. (2021). Cumulative exposure to melphalan chemotherapy and subsequent risk of developing acute myeloid leukemia and myelodysplastic syndromes in patients with multiple myeloma. European journal of haematology, 107(2), 275-282. https://doi.org/10.1111/ejh.13650
Jonsdottir, Gudbjorg, et al. "Cumulative exposure to melphalan chemotherapy and subsequent risk of developing acute myeloid leukemia and myelodysplastic syndromes in patients with multiple myeloma." European journal of haematology vol. 107,2 (2021): 275-282. doi: https://doi.org/10.1111/ejh.13650
Jonsdottir G, Björkholm M, Turesson I, Hultcrantz M, Diamond B, Porwit A, Landgren O, Kristinsson SY. Cumulative exposure to melphalan chemotherapy and subsequent risk of developing acute myeloid leukemia and myelodysplastic syndromes in patients with multiple myeloma. Eur J Haematol. 2021 Aug;107(2):275-282. doi: 10.1111/ejh.13650. Epub 2021 May 28. PMID: 33966293.
Copy Download .nbib Format: NLM
Survival, causes of death, and the prognostic role of comorbidities in chronic lymphocytic leukemia in the pre-ibrutinib era: A population-based study.

European journal of haematology

Steingrímsson V, Lund SH, Dickman PW, Weibull CE, Björkholm M, Landgren O, Kristinsson SY.
PMID: 34714556
Eur J Haematol. 2021 Oct 29; doi: 10.1111/ejh.13720. Epub 2021 Oct 29.

OBJECTIVE: To evaluate temporal trends in survival and causes of death in patients with chronic lymphocytic leukemia (CLL) in a nationwide study.METHODS: The cohort consisted of 13,009 Swedish CLL patients diagnosed 1982-2013. Relative survival (RS) and excess mortality rate...

Cite
Steingrímsson V, Lund SH, Dickman PW, et al. Survival, causes of death, and the prognostic role of comorbidities in chronic lymphocytic leukemia in the pre-ibrutinib era: A population-based study. Eur J Haematol. 2021;doi: 10.1111/ejh.13720.
Steingrímsson, V., Lund, S. H., Dickman, P. W., Weibull, C. E., Björkholm, M., Landgren, O., & Kristinsson, S. Y. (2021). Survival, causes of death, and the prognostic role of comorbidities in chronic lymphocytic leukemia in the pre-ibrutinib era: A population-based study. European journal of haematology, . https://doi.org/10.1111/ejh.13720
Steingrímsson, Vilhjálmur, et al. "Survival, causes of death, and the prognostic role of comorbidities in chronic lymphocytic leukemia in the pre-ibrutinib era: A population-based study." European journal of haematology vol. (2021). doi: https://doi.org/10.1111/ejh.13720
Steingrímsson V, Lund SH, Dickman PW, Weibull CE, Björkholm M, Landgren O, Kristinsson SY. Survival, causes of death, and the prognostic role of comorbidities in chronic lymphocytic leukemia in the pre-ibrutinib era: A population-based study. Eur J Haematol. 2021 Oct 29; doi: 10.1111/ejh.13720. Epub 2021 Oct 29. PMID: 34714556.
Copy Download .nbib Format: NLM
Healthcare resource utilisation and sickness absence in newly diagnosed multiple myeloma patients who did not undergo autologous stem cell transplantation: Trends in Sweden with the changing treatment landscape.

European journal of haematology

Borgsten F, Gatopoulou X, Pisini M, Tambour M, Schain F, Jones CV, Kwok KHM, Batyrbekova N, Björkholm M.
PMID: 33728732
Eur J Haematol. 2021 Jul;107(1):92-103. doi: 10.1111/ejh.13623. Epub 2021 May 05.

OBJECTIVES: The introduction of novel drugs has significantly improved outcomes for multiple myeloma (MM) patients. This study describes survival, healthcare resource utilisation and sickness absence in association with the changing MM treatment landscape over time, focussing on patients who...

Cite
Borgsten F, Gatopoulou X, Pisini M, et al. Healthcare resource utilisation and sickness absence in newly diagnosed multiple myeloma patients who did not undergo autologous stem cell transplantation: Trends in Sweden with the changing treatment landscape. Eur J Haematol. 2021;107(1):92-103doi: 10.1111/ejh.13623.
Borgsten, F., Gatopoulou, X., Pisini, M., Tambour, M., Schain, F., Jones, C. V., Kwok, K. H. M., Batyrbekova, N., & Björkholm, M. (2021). Healthcare resource utilisation and sickness absence in newly diagnosed multiple myeloma patients who did not undergo autologous stem cell transplantation: Trends in Sweden with the changing treatment landscape. European journal of haematology, 107(1), 92-103. https://doi.org/10.1111/ejh.13623
Borgsten, Fredrik, et al. "Healthcare resource utilisation and sickness absence in newly diagnosed multiple myeloma patients who did not undergo autologous stem cell transplantation: Trends in Sweden with the changing treatment landscape." European journal of haematology vol. 107,1 (2021): 92-103. doi: https://doi.org/10.1111/ejh.13623
Borgsten F, Gatopoulou X, Pisini M, Tambour M, Schain F, Jones CV, Kwok KHM, Batyrbekova N, Björkholm M. Healthcare resource utilisation and sickness absence in newly diagnosed multiple myeloma patients who did not undergo autologous stem cell transplantation: Trends in Sweden with the changing treatment landscape. Eur J Haematol. 2021 Jul;107(1):92-103. doi: 10.1111/ejh.13623. Epub 2021 May 05. PMID: 33728732.
Copy Download .nbib Format: NLM
A Randomized Comparison of Doxorubicin and Doxorubicin-DNA in the Treatment of Acute NonLymphoblastic Leukemia.

Leukemia & lymphoma

Paul C, Tidefelt U, Gahrton G, Björkholm M, Järnmark M, Killander A, Kimby E, Liliemark J, Lindeberg A, Lindquist R, Lockner D, Lönnqvist B, Mellstedt H, Merk K, Palmblad J, Peterson C, Simonsson B, Stalfelt AM, Sundström C, Wadman B, Wedelin C, Udén AM, Öberg G, Öst Å.
PMID: 27467426
Leuk Lymphoma. 1991;3(5):355-64. doi: 10.3109/10428199109070279.

In the light of previous findings that treatment of leukemia patients with DNA-linked doxorubicin gave higher doxorubicin concentrations in leukemic cells than treatment with doxorubicin alone, the Leukemia Group of Middle Sweden performed a randomized clinical trial to compare...

Cite
Paul C, Tidefelt U, Gahrton G, et al. A Randomized Comparison of Doxorubicin and Doxorubicin-DNA in the Treatment of Acute NonLymphoblastic Leukemia. Leuk Lymphoma. 1991;3(5):355-64doi: 10.3109/10428199109070279.
Paul, C., Tidefelt, U., Gahrton, G., Björkholm, M., Järnmark, M., Killander, A., Kimby, E., Liliemark, J., Lindeberg, A., Lindquist, R., Lockner, D., Lönnqvist, B., Mellstedt, H., Merk, K., Palmblad, J., Peterson, C., Simonsson, B., Stalfelt, A. M., Sundström, C., Wadman, B., Wedelin, C., Udén, A. M., Öberg, G., & Öst, �. �. (1991). A Randomized Comparison of Doxorubicin and Doxorubicin-DNA in the Treatment of Acute NonLymphoblastic Leukemia. Leukemia & lymphoma, 3(5), 355-64. https://doi.org/10.3109/10428199109070279
Paul, C, et al. "A Randomized Comparison of Doxorubicin and Doxorubicin-DNA in the Treatment of Acute NonLymphoblastic Leukemia." Leukemia & lymphoma vol. 3,5 (1991): 355-64. doi: https://doi.org/10.3109/10428199109070279
Paul C, Tidefelt U, Gahrton G, Björkholm M, Järnmark M, Killander A, Kimby E, Liliemark J, Lindeberg A, Lindquist R, Lockner D, Lönnqvist B, Mellstedt H, Merk K, Palmblad J, Peterson C, Simonsson B, Stalfelt AM, Sundström C, Wadman B, Wedelin C, Udén AM, Öberg G, Öst Å. A Randomized Comparison of Doxorubicin and Doxorubicin-DNA in the Treatment of Acute NonLymphoblastic Leukemia. Leuk Lymphoma. 1991;3(5):355-64. doi: 10.3109/10428199109070279. PMID: 27467426.
Copy Download .nbib Format: NLM
Cerebellar white matter in young adults with a familial risk for psychosis.

Psychiatry research. Neuroimaging

Pudas J, Björnholm L, Nikkinen J, Veijola J.
PMID: 30952031
Psychiatry Res Neuroimaging. 2019 May 30;287:41-48. doi: 10.1016/j.pscychresns.2019.03.012. Epub 2019 Mar 23.

No abstract available.

Cite
Pudas J, Björnholm L, Nikkinen J, et al. Cerebellar white matter in young adults with a familial risk for psychosis. Psychiatry Res Neuroimaging. 2019;287:41-48doi: 10.1016/j.pscychresns.2019.03.012.
Pudas, J., Björnholm, L., Nikkinen, J., & Veijola, J. (2019). Cerebellar white matter in young adults with a familial risk for psychosis. Psychiatry research. Neuroimaging, 28741-48. https://doi.org/10.1016/j.pscychresns.2019.03.012
Pudas, Juho, et al. "Cerebellar white matter in young adults with a familial risk for psychosis." Psychiatry research. Neuroimaging vol. 287 (2019): 41-48. doi: https://doi.org/10.1016/j.pscychresns.2019.03.012
Pudas J, Björnholm L, Nikkinen J, Veijola J. Cerebellar white matter in young adults with a familial risk for psychosis. Psychiatry Res Neuroimaging. 2019 May 30;287:41-48. doi: 10.1016/j.pscychresns.2019.03.012. Epub 2019 Mar 23. PMID: 30952031.
Copy Download .nbib Format: NLM
Lymphocyte and granulocyte function in nutritionally depleted patients. The effect of 2 weeks of total parenteral nutrition.

Clinical nutrition (Edinburgh, Scotland)

Björkholm M, Bark S, Backman L, Jarstrand C, Holm G.
PMID: 16843337
Clin Nutr. 1993 Dec;12(6):350-4. doi: 10.1016/0261-5614(93)90031-x.

Parenteral nutrition has been reported to restore impaired immune function in nutritionally depleted patients. Lymphocyte and granulocyte function were studied before and after 2 weeks of total parenteral nutrition (TPN) in 9 depleted patients, 5 with gastrointestinal cancer and...

Cite
Björkholm M, Bark S, Backman L, et al. Lymphocyte and granulocyte function in nutritionally depleted patients. The effect of 2 weeks of total parenteral nutrition. Clin Nutr. 1993;12(6):350-4doi: 10.1016/0261-5614(93)90031-x.
Björkholm, M., Bark, S., Backman, L., Jarstrand, C., & Holm, G. (1993). Lymphocyte and granulocyte function in nutritionally depleted patients. The effect of 2 weeks of total parenteral nutrition. Clinical nutrition (Edinburgh, Scotland), 12(6), 350-4. https://doi.org/10.1016/0261-5614(93)90031-x
Björkholm, M, et al. "Lymphocyte and granulocyte function in nutritionally depleted patients. The effect of 2 weeks of total parenteral nutrition." Clinical nutrition (Edinburgh, Scotland) vol. 12,6 (1993): 350-4. doi: https://doi.org/10.1016/0261-5614(93)90031-x
Björkholm M, Bark S, Backman L, Jarstrand C, Holm G. Lymphocyte and granulocyte function in nutritionally depleted patients. The effect of 2 weeks of total parenteral nutrition. Clin Nutr. 1993 Dec;12(6):350-4. doi: 10.1016/0261-5614(93)90031-x. PMID: 16843337.
Copy Download .nbib Format: NLM
Apollo 16 Geochemical X-ray Fluorescence Experiment: Preliminary Report.

Science (New York, N.Y.)

Adler I, Trombka J, Gerard J, Lowman P, Schmadebeck R, Blodget H, Eller E, Yin L, Lamothe R, Osswald G, Gorenstein P, Bjorkholm P, Gursky H, Harris B.
PMID: 17815621
Science. 1972 Jul 21;177(4045):256-9. doi: 10.1126/science.177.4045.256.

The lunar surface was mapped with respect to magnesium, aluminum, and silicon as aluminum/ silicon and magnesium/ silicon intensity ratios along the projected ground tracks swept out by the orbiting Apollo 16 spacecraft. The results confirm the observations made...

Cite
Adler I, Trombka J, Gerard J, et al. Apollo 16 Geochemical X-ray Fluorescence Experiment: Preliminary Report. Science. 1972;177(4045):256-9doi: 10.1126/science.177.4045.256.
Adler, I., Trombka, J., Gerard, J., Lowman, P., Schmadebeck, R., Blodget, H., Eller, E., Yin, L., Lamothe, R., Osswald, G., Gorenstein, P., Bjorkholm, P., Gursky, H., & Harris, B. (1972). Apollo 16 Geochemical X-ray Fluorescence Experiment: Preliminary Report. Science (New York, N.Y.), 177(4045), 256-9. https://doi.org/10.1126/science.177.4045.256
Adler, I, et al. "Apollo 16 Geochemical X-ray Fluorescence Experiment: Preliminary Report." Science (New York, N.Y.) vol. 177,4045 (1972): 256-9. doi: https://doi.org/10.1126/science.177.4045.256
Adler I, Trombka J, Gerard J, Lowman P, Schmadebeck R, Blodget H, Eller E, Yin L, Lamothe R, Osswald G, Gorenstein P, Bjorkholm P, Gursky H, Harris B. Apollo 16 Geochemical X-ray Fluorescence Experiment: Preliminary Report. Science. 1972 Jul 21;177(4045):256-9. doi: 10.1126/science.177.4045.256. PMID: 17815621.
Copy Download .nbib Format: NLM
Showing 13 to 24 of 36 entries